DE60229531D1 - Dna-pk-inhibitoren - Google Patents

Dna-pk-inhibitoren

Info

Publication number: DE60229531D1
Authority: DE; Germany
Prior art keywords: optionally substituted; dna; ring; activity; compounds
Prior art date: 2001-08-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60229531T

Other languages

English (en)

Inventor

Roger John Griffin

Bernard Thomas Golding

David Richard Newell

Hilary Alan Calvert

Nicola Jane Curtin

Ian Robert Hardcastle

Niall Morrison Barr Martin

Graeme Cameron Murray Smith

Laurent Jean Martin Rigoreau

Xiao-Ling Fan Cockcroft

Vincent Junior Ming-Lai Loh

Paul Workman

Florence Irene Raynaud

Bernard Paul Nutley

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cancer Research Technology Ltd

Original Assignee

Cancer Research Technology Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-14

Filing date

2002-08-14

Publication date

2008-12-04

2002-08-14 Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd

2008-12-04 Application granted granted Critical

2008-12-04 Publication of DE60229531D1 publication Critical patent/DE60229531D1/de

2022-08-15 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Pyrane Compounds (AREA)

DE60229531T 2001-08-14 2002-08-14 Dna-pk-inhibitoren Expired - Lifetime DE60229531D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0119865.4A GB0119865D0 (en)	2001-08-14	2001-08-14	DNA-PK inhibitors
PCT/GB2002/003781 WO2003024949A1 (en)	2001-08-14	2002-08-14	Dna-pk inhibitors

Publications (1)

Publication Number	Publication Date
DE60229531D1 true DE60229531D1 (de)	2008-12-04

Family

ID=9920420

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60229531T Expired - Lifetime DE60229531D1 (de)	2001-08-14	2002-08-14	Dna-pk-inhibitoren

Country Status (22)

Country	Link
US (2)	US7226918B2 (de)
EP (1)	EP1417196B1 (de)
JP (1)	JP4332032B2 (de)
KR (1)	KR100905457B1 (de)
CN (1)	CN1279034C (de)
AT (1)	ATE411987T1 (de)
AU (1)	AU2002362385B2 (de)
BR (1)	BR0211889A (de)
CA (1)	CA2454023A1 (de)
CY (1)	CY1110269T1 (de)
DE (1)	DE60229531D1 (de)
DK (1)	DK1417196T3 (de)
ES (1)	ES2315377T3 (de)
GB (2)	GB0119865D0 (de)
HU (1)	HUP0401052A3 (de)
MX (1)	MXPA04000804A (de)
NO (1)	NO20040636L (de)
NZ (1)	NZ530909A (de)
PL (1)	PL367081A1 (de)
PT (1)	PT1417196E (de)
WO (1)	WO2003024949A1 (de)
ZA (1)	ZA200400237B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0119863D0 (en) *	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
GB0119865D0 (en)	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
US7049313B2 (en)	2002-02-25	2006-05-23	Kudos Pharmaceuticals Ltd.	ATM inhibitors
JP2006523237A (ja) *	2003-04-03	2006-10-12	セマフォアファーマシューティカルズ，インコーポレイテッド	Ｐｉ−３キナーゼインヒビタープロドラッグ
KR20060066722A (ko)	2003-08-13	2006-06-16	쿠도스 파마슈티칼스 리미티드	아미노피론 및 ａｔｍ억제제로서의 이의 용도
WO2006032869A1 (en) *	2004-09-20	2006-03-30	Kudos Pharmaceuticals Limited	Dna-pk inhibitors
TW200638938A (en)	2005-02-09	2006-11-16	Kudos Pharm Ltd	ATM inhibitors
AR053358A1 (es) *	2005-04-15	2007-05-02	Cancer Rec Tech Ltd	Inhibidores de adn - pk
US7909830B2 (en)	2005-08-25	2011-03-22	Synthes Usa, Llc	Methods of spinal fixation and instrumentation
TW200745094A (en) *	2005-08-31	2007-12-16	Kudos Pharm Ltd	ATM inhibitor
US20090326223A1 (en) *	2006-07-18	2009-12-31	Roger John Griffin	Synthesis of 2-amino-substituted 4-oxo-4h-chromen-8.yl-trifluoro-methanesulfonic acid esters
CA2660560A1 (en) *	2006-08-16	2008-02-21	Boehringer Ingelheim International Gmbh	Pyrazine compounds, their use and methods of preparation
WO2009008991A2 (en) *	2007-07-06	2009-01-15	Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health	Dna-pkcs modulates energy regulation and brain function
UY31232A1 (es) *	2007-07-19	2009-03-02		Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
WO2009130469A1 (en) *	2008-04-25	2009-10-29	Kudos Pharmaceuticals Limited	Dna-pk inhibitors
WO2010136778A1 (en) *	2009-05-29	2010-12-02	Kudos Pharmaceuticals Limited	Dibenzothiophene derivatives as dna- pk inhibitors
AR077628A1 (es)	2009-07-02	2011-09-14	Sanofi Aventis	Derivados de 6-(morfolin-4-il)-pirimidin-4(3h)-ona, su preparacion y su utilizacion farmaceutica como inhibidores de la fosforilacion de akt(pkb)
FR2947548B1 (fr) *	2009-07-02	2012-05-18	Sanofi Aventis	Nouveaux derives de 1h-pyrimidin-2-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
HUE034503T2 (en)	2009-07-02	2018-02-28	Sanofi Sa	2,3-Dihydro-1-imidazo [1,2-a] pyrimidin-5-one derivatives, their preparation process and their use in medicine
JP5680638B2 (ja) *	2009-07-02	2015-03-04	サノフイ	新規な（６−オキソ−１，６−ジヒドロピリミジン−２−イル）アミド誘導体、この調製およびａｋｔ（ｐｋｂ）リン酸化インヒビターとしてのこの医薬的な使用
SG177464A1 (en)	2009-07-02	2012-02-28	Sanofi Sa	Novel 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof
FR2951170B1 (fr) *	2009-10-09	2011-12-02	Sanofi Aventis	Nouveaux derives de 1h-pyrimidin-2-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
US20130109687A1 (en) *	2010-04-30	2013-05-02	Gary J. Nabel	Methods of treating hiv infection: inhibition of dna dependent protein kinase
WO2012085244A1 (fr)	2010-12-23	2012-06-28	Sanofi	Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
HRP20170119T1 (hr)	2010-12-28	2017-03-24	Sanofi	Novi derivati pirimidina, njihovo pripremanje, te njihova farmaceutska uporaba kao inhibitora akt (pkb) fosforilacije
UY34013A (es) *	2011-04-13	2012-11-30	Astrazeneca Ab	?compuestos de cromenona con actividad anti-tumoral?.
FR2992316A1 (fr)	2012-06-22	2013-12-27	Sanofi Sa	Derives de pyrimidinones, leur preparation et leur application en therapeutique
FR2992314B1 (fr)	2012-06-22	2015-10-16	Sanofi Sa	Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
CN102977063A (zh) *	2012-11-26	2013-03-20	盛世泰科生物医药技术(苏州)有限公司	一种2-吗啡啉-8-苯基-4-苯并吡喃-4-酮的合成方法
SG11201507203RA (en)	2013-03-12	2015-10-29	Vertex Pharma	Dna-pk inhibitors
WO2015030057A1 (ja) *	2013-08-29	2015-03-05	富士フイルム株式会社	新規なモルホリン誘導体またはその塩
US11433047B2 (en)	2015-10-09	2022-09-06	Neurotheryx Canada Ltd.	Pharmaceutical compositions comprising one or more pyrone compounds, and their use for treating inflammatory and neurodegenerative diseases
WO2018183868A1 (en) *	2017-03-31	2018-10-04	Bioventures, Llc	Inhibitors of dna pk and uses thereof
CA3142521A1 (en)	2019-06-17	2020-12-24	Vertex Pharmaceuticals Incorporated	Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
BR112022021676A2 (pt)	2020-04-28	2023-01-31	Intellia Therapeutics Inc	Métodos de distribuição de célula in vitro
WO2022133246A1 (en)	2020-12-17	2022-06-23	Vertex Pharmaceuticals Incorporated	Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
KR20240017791A (ko)	2021-04-17	2024-02-08	인텔리아 테라퓨틱스, 인크.	Dna-의존적 단백질 키나제의 억제제 및 이의 조성물 및 용도
CN116903577A (zh) *	2023-07-03	2023-10-20	大连华一锂电科技有限公司	一种直接合成碳酸亚乙烯酯的方法
WO2025049481A1 (en)	2023-08-28	2025-03-06	Intellia Therapeutics, Inc.	Methods of editing an hla-a gene in vitro

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1303724A (de)	1969-05-14	1973-01-17
JPH0753725B2 (ja)	1987-10-08	1995-06-07	富山化学工業株式会社	４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en)	1988-10-28	1994-02-08	Hoechst Aktiengesellschaft	Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
JPH04502322A (ja) *	1988-12-21	1992-04-23	ジ・アップジョン・カンパニー	抗アテローム性動脈硬化症性および抗血栓性１―ベンゾピラン―４―オン類および２―アミノ―１，３―ベンゾオキサジン―４―オン類
US5703075A (en)	1988-12-21	1997-12-30	Pharmacia & Upjohn Company	Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH03215423A (ja)	1990-01-18	1991-09-20	Kyowa Hakko Kogyo Co Ltd	血管拡張剤
DK0525123T3 (da) *	1990-06-20	1998-05-04	Upjohn Co	Antiatherosklerotiske og antithrombotiske 1-benzopyran-4-oner og 2-amino-1,3-benzoxazin-4-oner
JPH05501886A (ja) *	1990-06-29	1993-04-08	ジ・アップジョン・カンパニー	抗アテローム性動脈硬化症性および抗血栓性２―アミノ―６―フェニル―４ｈ―ピラン―４―オン類
US5302613A (en)	1990-06-29	1994-04-12	The Upjohn Company	Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5252735A (en)	1990-06-29	1993-10-12	The Upjohn Company	Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
WO1994005283A1 (en)	1992-09-02	1994-03-17	Kyowa Hakko Kogyo Co., Ltd.	Anti-hiv drug
NZ263620A (en)	1993-04-09	1999-06-29	Toyama Chemical Co Ltd	The use of 4h-1-benzopyran-4-one derivatives as immunomodulators, cell adhesion inhibitors and agents for treating or preventing autoimmune diseases
US5378725A (en)	1993-07-19	1995-01-03	The Arizona Board Of Regents	Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5504103A (en)	1993-08-25	1996-04-02	Eli Lilly And Company	Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5441947A (en)	1993-08-25	1995-08-15	Eli Lilly And Company	Methods of inhibiting vascular restenosis
US5468773A (en)	1993-08-25	1995-11-21	Eli Lilly And Company	Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
CA2133815A1 (en)	1993-10-12	1995-04-13	Jeffrey Alan Dodge	Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US6632789B1 (en)	1994-04-29	2003-10-14	The United States Of America As Represented By The Secretary Of The Navy	Methods for modulating T cell responses by manipulating intracellular signal transduction
US5480906A (en)	1994-07-01	1996-01-02	Eli Lilly And Company	Stereochemical Wortmannin derivatives
GB9521987D0 (en)	1995-10-26	1996-01-03	Ludwig Inst Cancer Res	Phosphoinositide 3-kinase modulators
US5733920A (en)	1995-10-31	1998-03-31	Mitotix, Inc.	Inhibitors of cyclin dependent kinases
AU1461197A (en)	1995-11-16	1997-06-05	Icos Corporation	Cell cycle checkpoint pik-related kinase materials and methods
GB2302021A (en)	1996-10-16	1997-01-08	Lilly Co Eli	Inhibiting bone loss or resorption
WO1998055602A1 (en)	1997-06-06	1998-12-10	Mayo Foundation For Medical Education And Research	Screening for phosphatidylinositol related-kinase inhibitors
AU8068198A (en)	1997-06-13	1998-12-30	President And Fellows Of Harvard College	Methods for treating human cancers
FR2776291B1 (fr)	1998-03-18	2000-06-16	Pf Medicament	Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6348311B1 (en)	1999-02-10	2002-02-19	St. Jude Childre's Research Hospital	ATM kinase modulation for screening and therapies
US6387640B1 (en)	1999-02-10	2002-05-14	St. Jude Children's Research Hospital	ATM kinase modulation for screening and therapies
AU2001230426C1 (en) *	2000-01-24	2006-06-22	Astrazeneca Ab	Therapeutic morpholino-substituted compounds
US6699997B2 (en)	2000-06-28	2004-03-02	Teva Pharmaceutical Industries Ltd.	Carvedilol
AU2001288432A1 (en)	2000-09-01	2002-03-22	Icos Corporation	Materials and methods to potentiate cancer treatment
WO2002056912A2 (en)	2001-01-16	2002-07-25	Glaxo Group Limited	Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
GB0119865D0 (en)	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
GB0119863D0 (en)	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
US6894055B2 (en)	2001-10-24	2005-05-17	Iconix Pharmaceuticals Inc.	Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase
US6908932B2 (en)	2001-10-24	2005-06-21	Iconix Pharmaceuticals, Inc.	Modulators of phosphoinositide 3-kinase
SI1485377T1 (sl)	2002-02-25	2010-04-30	Kudos Pharm Ltd	Piranoni, uporabni kot inhibitorji ATM
US7049313B2 (en)	2002-02-25	2006-05-23	Kudos Pharmaceuticals Ltd.	ATM inhibitors
ATE491703T1 (de)	2002-04-30	2011-01-15	Kudos Pharm Ltd	Phthalazinonderivate
KR20060066722A (ko)	2003-08-13	2006-06-16	쿠도스 파마슈티칼스 리미티드	아미노피론 및 ａｔｍ억제제로서의 이의 용도
WO2006032869A1 (en)	2004-09-20	2006-03-30	Kudos Pharmaceuticals Limited	Dna-pk inhibitors
TW200638938A (en)	2005-02-09	2006-11-16	Kudos Pharm Ltd	ATM inhibitors
AR053358A1 (es)	2005-04-15	2007-05-02	Cancer Rec Tech Ltd	Inhibidores de adn - pk
UY31232A1 (es)	2007-07-19	2009-03-02		Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

2001
- 2001-08-14 GB GBGB0119865.4A patent/GB0119865D0/en not_active Ceased
2002
- 2002-08-14 CA CA002454023A patent/CA2454023A1/en not_active Abandoned
- 2002-08-14 PT PT02751439T patent/PT1417196E/pt unknown
- 2002-08-14 PL PL02367081A patent/PL367081A1/xx not_active Application Discontinuation
- 2002-08-14 US US10/486,816 patent/US7226918B2/en not_active Expired - Lifetime
- 2002-08-14 WO PCT/GB2002/003781 patent/WO2003024949A1/en active IP Right Grant
- 2002-08-14 BR BR0211889-0A patent/BR0211889A/pt not_active IP Right Cessation
- 2002-08-14 CN CNB028159780A patent/CN1279034C/zh not_active Expired - Fee Related
- 2002-08-14 MX MXPA04000804A patent/MXPA04000804A/es active IP Right Grant
- 2002-08-14 DE DE60229531T patent/DE60229531D1/de not_active Expired - Lifetime
- 2002-08-14 HU HU0401052A patent/HUP0401052A3/hu unknown
- 2002-08-14 AT AT02751439T patent/ATE411987T1/de active
- 2002-08-14 EP EP02751439A patent/EP1417196B1/de not_active Expired - Lifetime
- 2002-08-14 GB GB0401411A patent/GB2393653B/en not_active Expired - Fee Related
- 2002-08-14 NZ NZ530909A patent/NZ530909A/en not_active IP Right Cessation
- 2002-08-14 KR KR1020047002182A patent/KR100905457B1/ko not_active Expired - Fee Related
- 2002-08-14 JP JP2003528797A patent/JP4332032B2/ja not_active Expired - Fee Related
- 2002-08-14 DK DK02751439T patent/DK1417196T3/da active
- 2002-08-14 AU AU2002362385A patent/AU2002362385B2/en not_active Ceased
- 2002-08-14 ES ES02751439T patent/ES2315377T3/es not_active Expired - Lifetime
2004
- 2004-01-13 ZA ZA200400237A patent/ZA200400237B/xx unknown
- 2004-02-12 NO NO20040636A patent/NO20040636L/no not_active Application Discontinuation
2007
- 2007-06-05 US US11/758,332 patent/US7674823B2/en not_active Expired - Fee Related
2009
- 2009-01-14 CY CY20091100039T patent/CY1110269T1/el unknown

Also Published As

Publication number	Publication date
GB2393653A (en)	2004-04-07
ATE411987T1 (de)	2008-11-15
US7674823B2 (en)	2010-03-09
GB2393653B (en)	2005-02-02
US7226918B2 (en)	2007-06-05
EP1417196B1 (de)	2008-10-22
CA2454023A1 (en)	2003-03-27
GB0401411D0 (en)	2004-02-25
ES2315377T3 (es)	2009-04-01
BR0211889A (pt)	2004-09-21
KR20040032152A (ko)	2004-04-14
CN1279034C (zh)	2006-10-11
JP4332032B2 (ja)	2009-09-16
CY1110269T1 (el)	2015-01-14
DK1417196T3 (da)	2009-03-02
EP1417196A1 (de)	2004-05-12
KR100905457B1 (ko)	2009-07-02
PT1417196E (pt)	2009-01-02
CN1543457A (zh)	2004-11-03
GB0119865D0 (en)	2001-10-10
HUP0401052A3 (en)	2007-05-29
AU2002362385B2 (en)	2008-07-31
HK1070368A1 (en)	2005-06-17
PL367081A1 (en)	2005-02-21
ZA200400237B (en)	2004-08-18
MXPA04000804A (es)	2004-06-03
WO2003024949A1 (en)	2003-03-27
US20040192687A1 (en)	2004-09-30
JP2005503414A (ja)	2005-02-03
HUP0401052A2 (hu)	2004-09-28
US20070238729A1 (en)	2007-10-11
NO20040636L (no)	2004-04-02
NZ530909A (en)	2005-10-28

Publication	Publication Date	Title
DE60229531D1 (de)	2008-12-04	Dna-pk-inhibitoren
ZA200601595B (en)	2007-03-28	Aminopyrones and their use as ATM inhibitors
NO20071873L (no)	2007-06-15	DNA-PK inhibotorer.
TW200605883A (en)	2006-02-16	Condensed heterocycle derivative having HCV inhibitory activity
NO20004485D0 (no)	2000-09-08	Sykloalkenderivater, deres fremstilling og anvendelse
TW200638938A (en)	2006-11-16	ATM inhibitors
HUP0401303A2 (hu)	2004-12-28	Fungicid hatással rendelkező jódbenzopirán-4-on-származékok, előállításuk, alkalmazásuk és ilyeneket tartalmazó készítmények
EP1258252A4 (de)	2005-11-02	Inhibitoren der integrinexpression
DK1427720T3 (da)	2009-05-04	3-substitueret-4-pyrimidonderivater
WO2006055922A3 (en)	2006-12-21	Anthranilamide insecticides
AP1541A (en)	2006-01-11	New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors.
HUP0402025A2 (hu)	2005-02-28	Új benzofenon származékok és sóik és alkalmazásuk
ATE281430T1 (de)	2004-11-15	Anilin-derivate als stickstoffmonoxid synthase- inhibitoren
HUP0004477A2 (hu)	2001-02-28	Herbicid hatású 3-(1,2-benzizotiazol- vagy-izoxazol-5-il)-csoporttal helyettesített pirimidinszármazékok, intermedierjeik, előállításuk és alkalmazásuk
DK1847534T3 (da)	2011-08-29	Thiadiazolin-derivater til behandling af kræft
GB0119863D0 (en)	2001-10-10	DNA-PK inhibitors
YU18404A (sh)	2006-08-17	Hemijska jedinjenja
ATE449773T1 (de)	2009-12-15	Homomorpholinoxazolidinone als antibakterielle mittel
TW200738679A (en)	2007-10-16	Carboxamide compound and use of the same
TH76092A (th)	2006-03-02	เฮเทอโรแอริล เฟนิลยูเรีย

Legal Events

Date	Code	Title	Description
2009-11-12	8364	No opposition during term of opposition